CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03323034
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:06.530169+00:00
Published At: 2022-09-23T00:00:00+00:00
Record Updated At: 2024-10-22
Results Posted At: 2022-09-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Primary Central Nervous System Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Central Nervous System Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-10-22"
protocolSection.identificationModule.nctId: "NCT03323034"
protocolSection.identificationModule.officialTitle: "A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-09-23"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.